cyrilzakka/clinical-trials huggingface dataset:
Study of XL999 in Patients With Non-small Cell Lung Cancer

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.


Eligibility Criteria:
Inclusion Criteria:

* Males and females with histologically confirmed NSCLC
* Prior treatment with a platinum- or taxane containing regimen
* Stage IIIB with malignant effusion, stage IV or recurrent NSCLC that is not amenable to curative therapy (either surgery or radiation therapy)
* Measurable disease according to Response Criteria for Solid Tumors (RECIST)
* ECOG performance status of 0 or 1
* Life expectancy ≥3 months
* Adequate organ and marrow function
* No other malignancies within 5 years
* Signed informed consent

Exclusion Criteria:

* Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
* Use of any systemic anticancer therapy within 30 days of XL999 treatment
* More than 2 prior systemic cytotoxic chemotherapy regimens
* More than 1 prior agent targeted against VEGF or EGFR (eg, bevacizumab, erlotinib, or gefitinib)
* Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered \>30 days before study enrollment
* Uncontrolled and/or intercurrent illness
* History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
* Pregnant or breastfeeding females
* Known HIV
Mindfulness Intervention and Online Social Networking

This study aims to examine (a) the effects of mindfulness-based intervention on wellbeing including psychological, social, and emotional wellbeing, depressive symptoms, and stress and (b) the extent to which demographics, OSN use, and mindfulness mediate these effects.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old

Exclusion Criteria:

* have not complete the application form
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer

The purpose of this study is to determine the effectiveness of proton beam radiotherapy combined with chemotherapy for treatment of locally advanced non-small cell lung cancer.


Eligibility Criteria:
Inclusion Criteria:

* Clinical stage 2, 3A or 3B (unresectable)
* Histologic evidence of non-small cell carcinoma
* Age \> 18 years
* Karnofsky performance status 70 or greater
* No prior radiation to the chest
* No previous chemotherapy

Exclusion Criteria:

* Clinical stage 1 or 4
* Previous malignancies except for non-melanoma skin cancer unless disease free for \> 3 years
Clinical Effects of Gelified Ethanol Application in Cervical Disc Hernia

The aim of the study is to evaluate the clinical effects of Discogel® Radiopaque Gelified Ethanol as therapeutic substance for nucleolysis application in the patients with cervical disc hernia who had chronic pain and weakness on the neck, shoulders and arms.

This is a retrospective, single-center study that is going to be conducted from November 2013 to May 2016 on patients visiting the pain clinic of the hospital who were treated with DiscoGel® for cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy.

Data collected from medical record forms and electronic medical record system of the hospital were used in the retrospective analysis of medical data with regard to age, gender, complications.

A resident who has not involved in the study interviewed each patient by telephone on the follow up to collect the related information.

Eligibility Criteria:
Inclusion Criteria:

* continuous radicular pain radiating to the upper limb, with a duration ≥8 weeks and an intensity \>4/10 as rated by the patient on a visual analog scale (VAS)
* resistant to appropriate conservative treatment combining anti-inflammatory drugs and ozone-oxygen therapy, and confirmed by imaging with CT or MRI of a herniated disc putting pressure on a nerve root consistent with the clinical pain.

Exclusion Criteria:

* history of surgery at the cervical spine, contraindication to percutaneous chemonucleolysis (coagulopathy or infection), imaging results that did not support the clinical results, the presence of a herniated disc excluded or calcified on imaging, possible interference with pain evaluation due to any medical condition or treatment, involvement of incomplete data collection
Impact of Prolonged Cold-water Swimming on Heart Rate and Cardiac Function

A significant medical risk associated with hypothermia during exercise in a cold environment cardiac arrhythmia due to a possible autonomic conflict. However, little is known about the changes in heart rate and cardiac function after prolonged cold water swimming.

The investigators propose to measure the changes in core temperarure during and after a cold water swim at at a water temperature below 15.5°C qualifying for English Channel swim and to test the association with changes in heart rate variability, resting electrocardiogram and left ventricle function.


Eligibility Criteria:
Inclusion Criteria:

* swimmers taking part in the Channel Swim Camp
* swimmers above 18 years of age
* swimmers willing and able to give informed consent for participation in the study

Exclusion Criteria:

* swallowing disorder
* chronic gastrointestinal disease
* MRI scheduled within 48 hours after the race.
* known cardiac arythmia or cardiovascular disease
Prevention and Treatment of Hypertension Study (PATHS)

To evaluate the long-term effect of reduction of alcohol intake on blood pressure in moderate but non-dependent drinkers with mild hypertension or high normal blood pressure.

BACKGROUND:

Numerous observational epidemiologic studies have established ethanol intake as one of the most important determinants of blood pressure levels. However, data from intervention studies were very limited.

The study was an inter-agency agreement involving the Veterans Administration and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Protocol development occurred between October 1988 and June 1989. The protocol was approved by the VA Cooperative Studies Evaluation Committee in July 1989 and reviewed by a separate Data and Safety Monitoring Board in September 1989.

DESIGN NARRATIVE:

Subjects were randomized to intervention or control groups. Intervention aimed to reduce alcohol intake to no more than 14 drinks per week and 50 percent or less of each participant's baseline level. The intervention technique consisted of a cognitive-behavioral program, the intensive phase of which consisted of six counseling sessions over three months. Echocardiograms were obtained at baseline and six months after randomization. Biochemical markers were used to validate changes in alcohol consumption. The trial included an eighteen-month feasibility phase with six-month follow-up and a 36-month main trial with two years of follow-up. Recruitment for the full-scale trial ended in June 1993. Final study visits were conducted in September and October 1994.

The study completion date listed in this record was obtained from the "End Date" entered in the Query View Report System (QVR).

Eligibility Criteria:
Men and women with a diastolic blood pressure of 80 to 89 mm Hg and alcohol intake of 21 drinks or more per week.
Effect of Scapular Stabilization Exercises Versus Virtual Reality Exercises in Basketball Players With Scapular Dyskinesia

this study will be conducted to compare virtual reality and scapular stabilizing exercise among basketball player with scapular dyskinesia on scapular muscle performance, rounded shoulder, pain intensity , disability and hand grip strength

Scapular dyskinesia (SD) is an alteration in the normal position or motion of the scapula during coupled scapulohumeral movements. It is lack of control of static or dynamic positioning of the scapula relative to the thorax. It affects from 64% to 100% of patients with shoulder lesions. Scapular dyskinesia is a major etiological factor in overhead athletes' shoulder problems. Virtual Reality (VR) it allows individuals to interact and train with or within interesting and relatively realistic three-dimensional(3D) environments. VR and its simulated environments are well accepted in entertainment and computer game applications. However, what is not as well recognized is that VR offers the opportunity for intensive repetition of meaningful task-related activities necessary for effective rehabilitation. The scapular stabilization exercise in rehabilitation aims to Restore shoulder function; these exercises are a combination of scapular stabilization exercises, rotator cuff strengthening exercises, range of motion (ROM), proprioceptive neuromuscular facilitation (PNF), and stretching exercises. Physiotherapy is the mainstay management for several musculoskeletal disorders. sixty basketball athletes with dyskinesea will be assigned randomly to three equal groups; the first will receive Virtual reality exercise and routine exercise, and the second group will receive Stabilization exercise and routine exercise. and finally, the third group will receive routine exercise only for eight weeks

Eligibility Criteria:
Inclusion Criteria:

* ninety basketball players of both genders.
* Subjects with age between 20 and 25 years old.
* Subjects with Body Mass Index (BMI) ranging from 18 to 25 kg/m².

Exclusion Criteria:

* An injury within the four weeks before testing.
* Upper extremity fractures.
* Bilateral repetitive strain injuries
* Osteoarthritis on hand
Program for Screening and Prevention of Eating Disorders in Obese Young People in Vulnerable Neighborhoods of Marseille: an Action Research

Action research has been developed in this direction in order to use a tool to identify food disorder behavior among obese youths in their neighborhoods and social centers in vulnerable neighborhoods of Marseille, with the aim of a multi-professional therapeutic management (psychosocial support, theater) and a specialized orientation.

This program consists of the participation of each patient recruited in collective workshops. A total of 60 patients considered. Our hypothesis lies in the fact that for young people to participate in an adapted device, taking into account the global needs of young people and their entourage, would limit the deleterious effects of obesity and promote the young person's autonomy and allow him to be a actor in the request for care.

The project's objective is to provide support in the form of workshops with patients identified by the Marseille Hospitals Public Assistance Health Center as obese children and adolescents, in a precarious situation; to identify the presence of binge eating disorders and evaluate the impact of participation in these workshops on subsequent management by highly specialized professionals in food disorder behavior.

The mobile team (EM) of the Marseille Hospitals Public Assistance Health Center has the mission to inform, screen, support and guide the access to care of people in targeted neighborhoods, said to be vulnerable, by the city's policy of Marseille. The health space, a place of welcome and care, is located at a distance from any hospital structure within the most vulnerable neighborhoods of the city.

Eligibility Criteria:
Inclusion Criteria :

* Boys or girls aged 11 to 17
* Reside in the territory of intervention of the mobile team, i.e the 3rd, 14th, 15th and 16th arrondissement of Marseille, districts said to be vulnerable by the city's policy.
* Body mass index greater than or equal to IOTF-30 (HAS, 2011)
* Social precariousness score EPICES greater than or equal to 30riteria:
* Diagnosed Eating Disorder without medical and/or multi-professional care

Exclusion Criteria:

* Child with major difficulty of behavior
* Patient with medical care
Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

The hypothesis is tested that stimulation with angiotensin II after blockade of the AT1-receptor results in venodilation in human healthy subjects in vivo.


Eligibility Criteria:
Inclusion Criteria:

* healthy subjects

Exclusion Criteria:

* any relevant disease
Reciprocation vs Rotational Single-file Systems in Postoperative Pain

In this study, the researchers will investigate the effect of single-file reciprocating versus single-file rotational file systems on the postoperative pain in adult patients who have necrotic pulp and apical periodontitis. The participants will be assigned by chance to separate groups that compare 2 different treatments, reciprocating single-file system (Reciproc Blue) and rotational single-file system (OneShape). As a reference, Mtwo multi-file (full-sequence) will be used.

The infected root canal treatments will be performed using one-visit approach with either a reciprocating single-file system or a continuous rotational single-file system. (Reciproc Blue reciprocating single-file system vs OneShape rotational single-file system). The root canals will be completed in single-visit. The patients will record their postoperative pain during the follow-up period using a VAS scale.

Eligibility Criteria:
Inclusion Criteria:

* Participants who have in their mandibular or maxillary molar teeth necrotic pulp and apical periodontitis.

Exclusion Criteria:

* Pregnancy, drug hypersensitivity, cardiac problems, previously performed endodontics treatment.
Clinical Study of Behavior Problems in Children After Different Anesthesia Methods

The aim of this study is to investigate long-lasting or later behavioral changes in children in the context of different anesthesia techniques (Inhalation anesthesia vs. TIVA)

The process of surgery and anaesthesia can be an extremely frightening and stressful event for a child, and is frequently followed by negative postoperative behavioural changes. This Event could be associated with poor postoperative outcome and long term behavior problems like anxiety, eating or sleeping disorders. The aim of this study is to investigate long-lasting or later behavioral changes in children in the context of different anesthesia techniques (Inhalation anesthesia vs. TIVA). After anesthesia initiation, anesthesia maintenance should be done with sevoflurane or Tiva. The effect of behavioral changes in children in the context of anesthesia techniques should be evaluate by post hospitalisation behavior and Strengths and Difficulties Questionnaire at first, second and fourth week. Early postoperative problems like postoperative nausea and vomiting, pain level, pain therapy and postoperative awareness should be evaluate too.

Eligibility Criteria:
Inclusion Criteria:

* elective Operation
* operation in general anesthesia in combination with regional anesthesia
* Age 2-10 years
* ASA classification 1 or 2 (without severe basic disease or disability)

Exclusion Criteria:

* Lack of Consensus
* general anesthesia during the last 3 months before or 4 weeks after the procedure
* PONV prophylaxis with droperidol
* severe known growth factor
* mental pre-existing conditions and behavioral abnormalities
* contraindications for one of the used study medications
* insufficient regional anesthesia
* secondary intervention within of the 4-week follow-up
Duloxetine for the Treatment of Postpartum Depression

The purpose of this study is to assess whether the antidepressant, duloxetine, is equally effective as a treatment for subjects who have a Postpartum Onset Depression compared to subjects who have an onset of Major Depressive Disorder prior to delivery. The hypothesis is that duloxetine will be as effective in subjects with Postpartum Major Depressive Disorder as in subjects with a Major Depressive Disorder.

Study was terminated because of poor enrollment

Eligibility Criteria:
Inclusion Criteria:

* adult female subjects age 18 and above if onset of depression within 4 weeks of delivery,or onset of depression antenatally either during pregnancy or before pregnancy
* must score greater than or equal to 12 on the Edinburgh Postnatal Depression Scale
* speak English or Spanish
* have access to a telephone
* provide written and verbal consent

Exclusion Criteria:

* have current or lifetime psychosis
* an unstable medical condition
* hypertension
* narrow-angle glaucoma
* liver disease
* seizure disorders
* bulimia
* anorexia
* mania
* substance abuse disorders
* have a known hypersensitivity to duloxetine or any of the active ingredients
* are in need of inpatient hospital treatment with an excluded medication
* adolescents under the age of 18

Medication Exclusion

* other antidepressants
* antipsychotic agents
* quinolone antibiotics
* Type 1C antiarrhythmics
* daily benzodiazepines
* Treatment with a monoamine oxidase inhibitor
Pinto Beans and Glycemic Control in Adults With Type 2 Diabetes

This study examines the impact of daily consumption of ½ c pinto beans, compared to a control (½ c green beans), on fasting glucose, postprandial glucose and HbA1c concentrations in adults with type 2 diabetes mellitus (T2DM).

This study utilized a randomized, pretest-posttest, crossover (within-group) design, that includes two treatment periods \[control period (½ c. green beans each day) and pinto beans (½ c each day)\], each 12-weeks in duration with a 4- week wash-out period to determine the impact on fasting glucose, postprandial glucose and HbA1c concentrations. After a baseline wash-in period, 16 participants are randomly assigned to 2 treatment periods \[control period and pinto beans\], each 12-weeks in duration. On 28 randomized days during the wash-in period and interventions, participants keep diet records and measure a postprandial capillary glucose concentration using a glucometer 1 hour after the meal during which the pinto beans or control are consumed. Before and after each 12-week intervention, participants provide a fasted venous blood sample for glucose and HbA1c analyses.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of T2DM by a physician;
* currently attempting control of T2DM by diet or metformin;
* fasting glucose ≥ 90 mg/dL (confirmed by fasting blood draw or potential participant provided lab analysis conducted within last 30 days) and/or hemoglobin A1C ≥ 6.5% (confirmed by blood draw or potential participant provided lab analysis conducted within last 30 days);
* body mass index (BMI) of 22-40 kg/m2;
* no unresolved health conditions and no diagnosis of gastrointestinal disease;
* limited history of legume intake;
* willingness to follow study protocol, scheduling, and ability to come to the testing location;
* no recent weight gain or loss (\>10% over 6 months);
* no use of medications and/or dietary supplements other than metformin that affected glucose;
* women could not be pregnant or breastfeeding;
* habitual alcohol consumption had to be less than 2 drinks per day (specifically ≤ 720 ml of beer, 240 ml of wine, or 90 ml of hard liquor).

Exclusion Criteria:

* Non compliance with above inclusion criteria.
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (DAL)

This is a mono-centre, prospective, one-arm, unmask clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation compared to a single vision spectacle lens from the historical control group of another clinical trial NCT05331378. A total of 40 children will be recruited

As myopia is a growing worldwide problem, it is important to better understand the range of possible treatments to slow the progression of myopia. Spectacle lenses with aspherical lenslets were shown to be effective in reducing myopia progression and axial length elongation in children in the previous clinical trial (Bao et al. 2022). A dose-dependent effect was demonstrated, with higher lenslet asphericity having greater myopia control efficacy.

This open clinical trial will test the safety and effectiveness of a test lens designed to modify the area and amount of myopic defocus on the retina without compromising vision. The study population includes children in Singapore aged 8 to 13 years (40 subjects) at the time of commencing treatment. Axial length and spherical equivalent refraction will be the primary measure for myopia progression. Visual acuities will also be compared between test lenses and control lenses of the historical control group to determine the quality of vision using test lenses

Eligibility Criteria:
Inclusion Criteria:

* Volunteer subject and guardian, fluent English spoken, willing to follow protocol and able to read, comprehend and sign the informed consent \& assent form.
* 8 to 13 years old at time of informed consent and assent.
* Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.75 D in each eye.
* Astigmatism, if present, of not more than 1.50 D.
* Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D.
* Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
* Be in good general health based on his/her and parent's/guardian's knowledge. Absence of ocular disease with full ophthalmic examination. Without any ocular or systemic condition known to affect refractive status.
* Absence of strabismus by cover test at near or distance wearing correction.
* Absence of amblyopia
* Without ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.

Exclusion Criteria:

* Vulnerability of subject
* History of myopia control intervention
* Participation in any clinical study within 30 days of the Baseline visit.
Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating children who have relapsed or refractory acute lymphoblastic leukemia or acute myelogenous leukemia.

OBJECTIVES:

* Determine the response rate in children with relapsed or refractory acute lymphoblastic leukemia or acute myelogenous leukemia treated with gemcitabine.
* Assess the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to disease histology (acute lymphoblastic leukemia vs acute myelogenous leukemia).

Patients receive gemcitabine IV over 6 hours weekly for 3 weeks. Treatment repeats every 4 weeks for a maximum of 2 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: Approximately 10-20 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of relapsed acute lymphoblastic leukemia or acute myelogenous leukemia

  * M3 marrow (at least 25% blasts in bone marrow aspirate)
  * Refractory to conventional therapy

PATIENT CHARACTERISTICS:

Age:

* 21 and under at diagnosis

Performance status:

* ECOG 0-2 OR
* Zubrod 0-2

Life expectancy:

* At least 2 months

Hematopoietic:

* Not specified

Hepatic:

* Bilirubin normal
* SGOT or SGPT no greater than 2.5 times upper limit of normal

Renal:

* Creatinine normal OR
* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min

Other:

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No concurrent immunomodulating agents

Chemotherapy:

* At least 2 weeks since prior chemotherapy
* No other concurrent chemotherapy for cancer

Endocrine therapy:

* No concurrent corticosteroids except for treatment of adrenal crises with suppressed pituitary/adrenal response
* Concurrent low-dose hydrocortisone (less than 100 mg/m2) allowed for allergic reactions to amphotericin or transfusions

Radiotherapy:

* Concurrent radiotherapy to localized painful lesions allowed

Surgery:

* Not specified

Other:

* Recovered from any prior therapy